PBMC induced TCM and application

An immune cell and memory technology, applied in the application field of memory immune cells (TCM), can solve the problems of difficult long-term survival of immune cells and lack of targeting, and can solve the problems of poor T cell proliferation and immune incompetence. Effect

Inactive Publication Date: 2017-11-21
路春光
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In order to solve the problem of long-term survival of immune cells in vivo and lack of targeting in adoptive cell therapy technology; this application provides a method for isolating and purifying memory T cells from cry

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] 1. Isolation and cryopreservation of PBMC cells:

[0037] a. Separation of PBMC cells: Peripheral blood was evenly divided into 50 mL centrifuge tubes with an electric aspirator, with no more than 35 mL per tube, 931 g, centrifuged for 8 min, and the upper layer of plasma was sucked into the 50 mL centrifuge tube, and 1.5 mL in EP tubes, labeled, and stored at -80°C. Dilute the blood cells with NA so that the ratio of blood cells: NA is 1:1, mix evenly and slowly add to the corresponding upper layer of liquid A to form a complete interface. 596 g, centrifuged for 20 min. Visible stratification. Aspirate and discard the supernatant of the first layer, and carefully and gently aspirate the second layer of white cell layer into different clean 50 mL centrifuge tubes. Add NA to each tube respectively, dilute and mix, and dilute to 40mL / tube. 931 g, centrifuged for 8 min. Discard the supernatant and add NA to resuspend the cells. The cell suspension was collected for c...

Embodiment 2

[0051] On the basis of Example 1, the TCM cells were sorted and purified, and induced and transfected in vitro, as follows

[0052] 1. Magnetic bead sorting of T cell subsets:

[0053] (1) Cell count.

[0054] (2) Prepare a single cell suspension (filtered with a 30-pore nylon mesh).

[0055] (3) Add buffer to wash cells, centrifuge at 1500rpm, 5min (4-8°C)

[0056] (4) Add 80ul / 107 cells of buffer.

[0057] (5) Add 20ul / 107 cells of antibody-coated magnetic beads.

[0058] (6) Incubate at 4-8°C for 10 minutes.

[0059] (7) Add 1ml / 107 cells of buffer to wash the cells and centrifuge at 1500rpm for 5min (4-8°C).

[0060] (8) Add 500ul / 107 cells of buffer to resuspend the cells.

[0061] (9) Prepare the separation column and wash the MS column with 500ul of buffer.

[0062] (10) Carefully add the cell suspension to the bottom surface of the sorting column.

[0063] (11) Rinse the column with 500ul of buffer solution (add new liquid each time there is no residual liquid)...

Embodiment 3

[0073] On the basis of embodiment 2 formula a, carry out the selection of induction formula

[0074] On the 1st day after isolation, the primary treatment was completed with 1000IU / ml IFN-γ, anti-human 130ng / ml CD3 monoclonal antibody, anti-human 110ng / ml CD28 monoclonal antibody, recombinant human 1000IU / ml IL-2, and 120u / mL IL-1α. Stimulate. Half of the medium was changed every 2 days, and recombinant human IL-2 (final concentration of 1000 IU / ml), 800 u / mL IL-7 and 800 u / mL recombinant human IL-15 were added.

[0075] The isolated PBMCs were resuspended with X-VIVO15, and the initial stimulation was completed with anti-human 130ng / mL CD3 monoclonal antibody, 110ng / mL anti-human CD28 monoclonal antibody and 1000u / mL recombinant human IL-2. The medium was changed in half every 2 days, and 1000 u / mL recombinant human IL-2 and 800 u / mL recombinant human IL-15 were added. On the basis of traditional TCM cell culture, IFN-γ, IL-1α and recombinant human cytokine IL-7 were added....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the technical field of immune cell targeted therapy, in particular to a kind of human peripheral blood mononuclear cells induced to differentiate into memory immune cells. TCM cells induced by frozen peripheral blood mononuclear cells provide a basis for clinical tumor treatment, and can Resuscitate cells at any time according to the treatment plan of tumor patients, which solves the problem of poor T cell proliferation and immune incompetence in tumor patients; at present, it is difficult for the reinfused immune cells, especially cloned effector T cells, to survive for a long time in the body, which greatly affects the adoptiveness Clinical efficacy of cell therapy. Memory T cells have long-term memory, and TCM cells are transfected with TCR genes to endow TCM cells with targeting.

Description

technical field [0001] The present invention relates to the technical field of immune cell targeted therapy, in particular to human peripheral blood mononuclear cells induced to differentiate into memory immune cells (TCM), and also relates to the application of memory immune cells (TCM). Background technique [0002] Adoptive cell therapy technology provides an effective method for breaking the central and peripheral immune tolerance of tumor patients, restoring or enhancing their anti-tumor immune function. However, there are still many problems to be solved, including: 1) how to obtain a sufficient number of tumor-reactive T cells is the most critical factor in determining the effect of adoptive cell therapy; 2) the current reinfusion of immune cells, especially cloned CD8+ It is difficult for T cells to survive for a long time in the body, which greatly affects the clinical efficacy of adoptive cell therapy. [0003] Memory T cells can be rapidly activated to exert im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/10A61K35/17A61P35/00
CPCC12N5/0636A61K35/17C07K14/7051C12N5/0638C12N2501/2301C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/24C12N2501/51C12N2501/515C12N2510/00
Inventor 路春光
Owner 路春光
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products